Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

Ihab Alomari, MD, FACC Assistant professor – Interventional Cardiology University of California, Irvine Division of Cardiology Cath Lab Essentials : LV.

Advertisements

IABP-SHOCK II Score Stratifies Patient Risk in CS after AMI

Improving Outcomes in Cardiogenic Shock

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 TAVI with a self-expanding valve in

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Cardiogenic Shock Cardiology Clinics

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Pathological specimens showing the most common reasons for bioprosthetic valve failure Figure 2 | Pathological specimens showing the most common.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 1 Anatomy of the femoral artery

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Three-year survival rates on the basis of body composition

Nat. Rev. Cardiol. doi: /nrcardio

Figure 8 4D magnetic resonance imaging patterns

Figure 4 Valve-in-valve implantations in degenerated surgical valves

A Hard Look at Cardiogenic Shock: IABP-SHOCK II Revisited

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Health-care system today

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 PCI strategies in patients with STEMI and multivessel disease

Figure 1 Decision tree integrating the assessment,

Figure 4 TAVI for bicuspid aortic valve disease

Figure 1 Types of surgical and transcatheter aortic valves

Figure 3 Neural crest cell migration

Figure 2 Global cost of HF per capita in 2012

Figure 2 A patient with aortic stenosis and mitral regurgitation

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Manual thrombus aspiration

Figure 1 Milestones in coronary angioplasty

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Juan J. Russo et al. JACC 2019;73:

Figure 4 Observational studies on multiple treatment strategies

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 The neurogenic components of angina

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Kaplan-Meier estimates of all-cause mortality at 30 days.

Independent predictors of all-cause mortality at 30 days.

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.96 Figure 2 An analysis of potentialin crement a l costof shifting from using intra-aortic balloon pumps (IABP) to percutaneous left ventricular assist devices (pVAD) Figure 2 | An analysis of potential incremental cost of shifting from using intra-aortic balloon pumps (IABP) to percutaneous left ventricular assist devices (pVAD). The data show an incremental increase in cost of $33,957,839 for the hospital system in the USA associated with use of pVAD in patients with cardiogenic shock undergoing percutaneous coronary intervention, without an associated improvement in mortality, reduced hospital length of stay, or hospital readmission. Reprinted from Shah, A. et al. Clinical and economic effectiveness of percutaneous ventricular assist devices for high-risk patients undergoing percutaneous coronary intervention. J. Invasive Cardiol. 27, 148–154 (2015), with permission from HMP Communications. Reprinted from Shah, A. et al. Clinical and economic effectiveness of percutaneous ventricular assist devices for high-risk patients undergoing percutaneous coronary intervention. J. Invasive Cardiol. 27, 148–154 (2015), with permission from HMP Communications Reyentovich, A. et al. (2016) Management of refractory cardiogenic shock Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.96